Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Antimicrobial resistance is a major public health problem globally. Likewise, forms of
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …

Background In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that
are more effective, shorter, and have a more acceptable side-effect profile than current …

Background The bedaquiline–pretomanid–linezolid regimen has been reported to have
90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events …

The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …

Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …

Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis, an infectious
disease with one of the highest morbidity and mortality rates worldwide. Leveraging its …

Background The STREAM stage 1 trial showed that a 9-month regimen for the treatment of
rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended …

Molecular tests for tuberculosis (TB) have the potential to help reach the three million people
with TB who are undiagnosed or not reported each year and to improve the quality of care …

Background Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) remain
low globally. Availability of newer drugs has given scope to develop regimens that can be …